United Therapeutics Corporation Scheduled to Participate in the Leerink Partners Global Biopharma Conference 2024

United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.

The session is scheduled for Tuesday, March 12, 2024, from 1:40 p.m. to 2:10 p.m., Eastern Daylight Time, and will be accessible via live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. A recorded version of the session will also be available approximately 24 hours after its conclusion and will remain accessible for 90 days.

United Therapeutics: Driving Innovation

United Therapeutics is committed to addressing unmet medical needs by leveraging our passion, creativity, and perseverance. As a public benefit corporation (PBC), we are dedicated to both enhancing patient care and delivering value to our stakeholders. Pioneering a unique approach, we are the first publicly-traded biotech or pharmaceutical company structured as a PBC. Our core mission is to advance novel pharmaceutical therapies and technologies to broaden the availability of transplantable organs, thereby fostering a brighter future for patients.

To gain further insight into our PBC model, visit: unither.com/pbc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements encompass our commitment to innovating for patients, benefiting stakeholders, and pursuing our public benefit purpose. However, such statements are subject to inherent risks and uncertainties, as outlined in our periodic reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated outcomes. Accordingly, these forward-looking statements are accompanied by cautionary language and risk factors delineated in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We invoke the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for these forward-looking statements. The information provided herein is current as of March 5, 2024, and we undertake no obligation to update or revise the content contained in this press release, whether due to new information, future events, or any other circumstances.

Source Link:

Newsletter Updates

Enter your email address below and subscribe to our newsletter